ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience.

A. Baghban,1 K. Belfield,2 M. Azar,1 E. Cohen,2 M. Malinis.1

1Infectious Diseases, Yale University, New Haven, CT
2Pharmacy, YNHH, New Haven, CT

Meeting: 2017 American Transplant Congress

Abstract number: A276

Keywords: Cytomeglovirus, Kidney transplantation, Outcome, Prophylaxis

Session Information

Date: Saturday, April 29, 2017

Session Name: Poster Session A: Viral Conundrums

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall D1

Related Abstracts
  • Low Dose Valganciclovir Is an Effective Prophylaxis Against Cytomegalovirus in High Risk (Donor+/ Recipient-) Kidney Transplants Recipients
  • Standard Dose Valganciclovir Prophylaxis for High-Risk Kidney Transplant Recipients Reduces Incidences of Breakthrough and Resistant Cytomegalovirus Infection.

Introduction

Current guidelines on cytomegalovirus (CMV) prophylaxis following organ transplant recommend using valganciclovir (VGCV) 900 mg daily for high (CMV D+/R-) and intermediate (CMV R+) risk renal transplant (RT) patients with normal creatinine clearance. Potential benefits of low dose VGCV regimens include decreased drug-related side effects and cost. Breakthrough viremia and resistant CMV are intuitive concerns with reduced antiviral dosing. Here, we describe our center's experience using low dose VGCV among CMV R+ RT patients.

Methods

CMV R+ RT patients who received kidneys between 2/1/2013 and 3/31/2015 and had at least 6 months of follow-up after completion of CMV prophylaxis were included. Patients received VGCV 450 mg daily, and the dose was adjusted for renal function. CMV infection (CMVI) was defined as any detectable viremia. CMV disease (CMVD) was classified into CMV viral syndrome and tissue-invasive disease.

Results

Of 235 renal transplants, 101 met inclusion criteria. The incidence of CMVI and CMVD are reported in Table 1. There were no cases of CMV resistance. More CMV infected patients experienced acute cellular rejection (ACR) at 9/21 (42.86%) compared to 8/80 (10.0%) patients without CMVI (p=0.001). Only 1 patient experienced ACR prior to CMV diagnosis, all others occurred subsequently. Virus-associated malignancies occurred in 2/21 (4.76%) patients with CMVI compared to no patients without CMVI (p=0.042).

There was a trend towards increased mortality in patients with CMVI with 3/21 (14.29%) versus 3/80 (3.75%) deaths, however, this did not achieve significance (p=0.102). Baseline characteristics, graft loss, and opportunistic infections were similar between groups.

CMV classification Number of patients
Viral syndrome 13/101 (12.87%)
Tissue invasive 2/101 (1.98%)
Asymptomatic viremia 6/101 (5.94%)
Total CMV Disease 15/101 (14.85%)
Total CMV infection 21/101 (20.79%)

Conclusions

Reduced dose VGCV was associated with a high incidence of CMVI and CMVD in this study, but no cases of CMV resistance were identified. Further studies are necessary to determine whether low dose VGCV prophylaxis is non-inferior to guideline-recommended dosing in this patient population. Reductions in immunosuppression following diagnosis of CMVI may be associated with the observed increase in ACR.

CITATION INFORMATION: Baghban A, Belfield K, Azar M, Cohen E, Malinis M. Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Baghban A, Belfield K, Azar M, Cohen E, Malinis M. Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/low-dose-valganciclovir-for-cytomegalovirus-prophylaxis-in-intermediate-risk-renal-transplants-a-single-center-experience/. Accessed January 16, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.